Introduction

Vulva cancer is a rare and fourth cause of gynecological cancer with prevalence around 4% worldwide. The most histologic type of vulvar cancers are squamous cell carcinomas, which account for 90% of all types.\[^1\]

The incidence is higher among old and postmenopausal patients.\[^2\] Mean age of women with vulvar cancer is between 64 and 70 years.\[^3\]

Vulvar intraepithelial neoplasia (VIN), HPV infection, squamous hyperplasia, lichen sclerosis, smoking, and immunosuppression were mentioned as risk factors.\[^4\]

There is a strong correlation between disease survival with lymph node status and the stage of disease.\[^5\] Recent studies showed that the disease is diagnosed at the early stage without lymph node involvement, the survival rate reached to 90%.\[^6\] Although, surgery is the gold standard of treatment, conservative surgery such as local excision of tumor with free margin rather than decrease of psychosexual consequence and morbidity of groin lymph node dissection than radical vulvectomy is preferred. Chemotherapy and radiotherapy are the other modalities for unresectable disease.\[^7\]

In Iran as a developing country we have no survey on vulvar cancer incidence or prevalence and long-term Survivals. Our study was carried out to determine demographic, treatment modalities, and survival rate of patients with vulvar cancer at medical university of Tehran, main referral center of gynecologic cancer of country over a period of 20 years.
**Materials and Methods**

In this retrospective cohort study, we evaluated medical records of patients with vulvar cancer who referred during 20 years (1998–2018) to Oncology and Gynecology department of Emam-Khomeini Hospital (EKH) of medical university of Tehran — the main referral center for gynecological cancer throughout the country — Iran. Patients with pathologically report of vulvar cancer entered into study.

Demographic data such as age, parity, menopausity state, history of medical disease, age onset of cancer, signs and stage of disease, treatment modalities, and so on were recorded with questionnaire.

Staging in our study was performed based on clinical examination, imaging, and pathological report after a complete surgery.

Vulvectomy or radical local excision of tumor and inguinofemoral lymphadenectomy were done for early stage (stages I and II) vulvar cancer.

Cases with stage III that had tumor resection capability were under initial surgery, those who were unable to be resected because of proximity to the urethra and anus were under three chemotherapy sessions, and then surgery was performed for them.

Patients with stage IV of disease referred for chemotherapy or radiotherapy. Adjuvant radiotherapy after surgery was done for patients with pathology of positive lymph node, size of tumor >4 cm or if the tumor-free surgical margins were <8 mm and further excision was not possible.

The outcome of patients (recurrence, death, and alive) were evaluated by a phone call. Recurrence time was calculated from last date of treatment up to time of recurrence diagnosis. Disease-free survival was considered as the date of primary treatment to date of death, or ended to palliative treatment.

Patients who did not respond to a call and their file information was incomplete, their being alive or dead was checked by referring to the site of Behesht Zahra Organization (State Death Registration System).

The study was approved by the Committee for Ethics of Tehran University of Medical Science. (IR.TUMS.IKHC.REC.1397.166).

The authors of the study were committed to the principles of the Helsinki Convention. Data were analyzed with IBM SPSS statistics version 24. Means were compared using Student’s t-test. Survival analysis was performed using Kaplan-Meier test. \( P < 0.05 \) was considered statistically significant.

**Results**

A total of 106 women presented to EKH with vulvar cancer between January 1998 and December 2018. The mean age of patients was 59.2 years (range 23-86 years). As age

| Table 1: Demographic data of patients |
|--------------------------------------|
| **Number**  | **Percentage (%)** | **P**  |
| **Age range (years)** |  |  |
| <30 | 3 | 2.8 | 0.03 |
| 30-39 | 7 | 6.6 |  |
| 40-49 | 17 | 16 |  |
| 50-59 | 21 | 19.8 |  |
| 60-69 | 22 | 20.8 |  |
| 70-79 | 26 | 24.5 |  |
| 80-89 | 10 | 9.4 |  |
| **Mean age** | 59.2±14.7 |  |
| **Parity** |  | 0.0001 |
| Nulliparous | 8 | 7.5 |  |
| Multiparous | 98 | 92.5 |  |
| **Parity, median (range)** | 5 (0-13) |  |
| **Menopausal status** |  | 0.0001 |
| Premenopausal | 17 | 15.1 |  |
| Postmenopausal | 85 | 80.2 |  |
| **Pap smear** |  |  |
| Normal | 103 | 97.2 | 0.001 |
| Abnormal | 3 | 2.8 |  |
| **Past medical Hx** |  | 0.0001 |
| Yes (HTN, diabetes) | 22 | 20.8 |  |
| No | 84 | 79.2 |  |

| Table 2: Annual distribution of patients with vulvar cancer |
|---------------------------------------------|
| **Year** | **Number of cases (n)** | **Percentage (%)** |
| 1998 | 4 | 4.1 |
| 1999 | 2 | 2.1 |
| 2000 | 3 | 2.8 |
| 2001 | 5 | 4.7 |
| 2002 | 3 | 2.8 |
| 2003 | 6 | 5.7 |
| 2004 | 4 | 3.8 |
| 2005 | 7 | 6.6 |
| 2006 | 9 | 8.5 |
| 2007 | 8 | 7.5 |
| 2008 | 9 | 8.5 |
| 2009 | 4 | 3.8 |
| 2010 | 3 | 2.8 |
| 2011 | 3 | 2.8 |
| 2012 | 6 | 5.7 |
| 2013 | 3 | 2.8 |
| 2014 | 3 | 2.8 |
| 2015 | 4 | 3.8 |
| 2016 | 6 | 5.7 |
| 2017 | 8 | 7.5 |
| 2018 | 6 | 5.7 |
| **Total** | **106** | **100.0** |
| **Mean** | **5.3 case per year** |  |
distribution presented in Table 1, only 25% of patients were <50 years. Most incidence of vulvar cancer was diagnosed in the year 2006 [Table 2]; the average per year was 5.3 cases.

Vulvar cancer significantly was more in multiparous patients than nulliparous ($P < 0.001$) and menopause patients than premenopause ($P < 0.001$). Details of demographic data are shown in Table 1.

The most obvious manifestation of vulvar cancer in our patients was a mass with most sign of pruritus. The most site of tumor involvement was major labial (39.1%), minor labial (27%), and clitoris (17.5%) respectively.

Squamous cell carcinoma was the most pathology of vulvar cancer in this study [Table 3].

Table 4 presents details of primary treatments for patients. Ninety patients (84.9%) had surgery as a primary treatment, 48 (53.3%) of them received adjuvant radiotherapy or chemoradiation after surgery. Sixteen patients (15.1%) had Chemoradiation as a primary treatment because of advanced-stage cancer of FIGO stage IV.

Eighty two (77.4%) patients had radical vulvectomy+ bilateral inguinofemoral lymphadenectomy, five (4.7%) hemivulvectomy, and two (1.2%) had wide local excision.

In all, 58 patients answered our phone calls and 55 cases (43.1%) had recurrence: 2 (12.5%) of patients without surgery and 23 (25%) with primary surgery treatment ($P = 0.1$). Mean duration of patients’ follow up was $82.4 \pm 68.3$ (1–200) month.

Five-year survival of patients in all stages was 76% [Figure 1]. Mean time of recurrence was 20 month (1-72 month). Two-year survival in those who had recurrence <2 years was 25% versus those who did not (87%).

### Discussion

There is paucity of information on vulvar cancer epidemiology and prognosis in Iran, as a upper-middle income country located in middle east with a wide area and almost 80 million population. This is the only study in Iran on vulvar cancer. Over a period of 20 years, we founded 106 patients of primary cancer of vulva at EKH. Annual incidence in our study was 5.3 per cases. These findings proved rarity of vulvar tumors as the fourth gynecological cancer.[7]

Mean age of our patients was 59.2 ± 14.7 years. It was resemble to Amavi et al study. Mean age in US was 68 years and 70 years in Ciszko study [Table 5].

The most number of patients was in the age range of 70–79 years, 10 years older than Indian people in Singh et al study and similar to US and European countries [23].

In Okeke et al study, this prevalence in Nigerian patients were found in fifth and sixth decades.

Vulvar cancer is the elderly disease in Iran. Only one fourth of our patients were below 50 years. It is comparable with Buttmann-Schweiger and Baantrup findings, which were 11.5% and 23%, respectively.

SCC was the most pathology (74.5%). Like 73% in Okolo study and 75% in Schuurman et al findings.

Vulvar cancer is seen in two age groups of the elderly and young people. In the elderly and menopause, it usually occurs in chronic illnesses associated with the P53 gene mutations, which is observed in advanced countries with high life expectancy. Another type is related to the HPV virus and observed in young people.
In our study, only three abnormal pap smears were observed. According to this finding and the lower probability of HPV patients, occurring vulvar cancer in higher ages in statistical population can be justified.

In our study, 54.7% of women diagnosed at stages III and IV which was similar to other studies. According to FIGO, in Ciszko study\(^\text{[11]}\), 68% of cases vulvar cancer was detected in II, III or IVa stage. Moreover, 39% of patients in Amavi study\(^\text{[9]}\) and 53.3% in Butt \(\text{et al}\).\(^\text{[3]}\) were at stages III and IV.

Our finding is in contrast with Stroup \(\text{et al}\).,\(^\text{[19]}\) 90% of cases were diagnosed in early stages, and 25% with stages III and IV.

Almost half of our patients referred in stages III and IV, which may be for referring to gynecologists for examination and check-up in elderly people in cities and rural areas is rarely done due to cultural issues, a sense of shame of showing genital area to other, lack of awareness and financial resources. Hence, most patients have suspicious unbearable symptoms when refer.

Five-year survival was 73% in the surgical group that was upper than other studies [Table 5]. Studies have shown that surgery leads to survival up to 90%,\(^\text{[20]}\) One possible reason for this is that the number of people who were under surgery was higher than all other studies in our study (84.9%), because all patients in stage III except one case that was under chemoradiation due to high age and underlying disease, other cases that had tumor resection capability were under initial surgery. This finding confirms the effectiveness of surgery as an initial treatment in patients with vulvar cancer.

In Singh study,\(^\text{[12]}\) all patients of stage III were under chemoradiation. [Table 5]

In Dadzie’s study\(^\text{[20]}\) in Ghana, 70% of patients were in stage IV and only 9% of patients were under initial surgery and overall five-year survival was 36.7%, which is in a worse situation than Iran.

However, 53.3% of our patients needed radiotherapy after surgery, which was 40.7% in Butt \(\text{et al}\).\(^\text{[3]}\) study.

Two-year survival rate was 37.5% in the group treated with non-surgical procedures. Six out of 16 people died, but the exact time of death was not measurable due to lack of proper follow up.

The most amount of type of operation in our study was radical vulvectomy + Ind, which can also contribute to the survival rate in the study, although postoperative morbidity in this type of surgery increases.

Vulvectomy surgery was performed with three incisions, one in the vulvar area and two in the groin regions for inguinofemoral lymphadenectomy. Studies have shown that this surgical technique will reduce the severity of postoperative complications.\(^\text{[11,23]}\)

In our study, patients from different cities and distant ways were referred to our health center. After surgery, due to lack of good financial support and the medical costs, they came back to health centers of their city for post-surgical following and we could not investigate morbidity after surgery or other therapies on these patients.

The results of our study, Iran is placed among developed and non-developed countries in terms of the prevalence of vulvar cancer, the mean age of the disease, the response to therapeutic modalities, and the survival rate.

**Limitations**

Owing to the change in the telephone number, it was not possible to make phone calls to many people and to be aware of the current situation of these people.

As patients did not come back after surgery, we could not access the pathologic reports of some of these patients and information such as lymph node and marginal involvement in all patients could not be assessed. We did not have good assessment of long-term morbidity of surgery or other modalities.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Saito T, Kato K. Management of lymph nodes in the treatment of vulvar cancer. Int J Clin Oncol 2007;12:187-91.
2. Ansink AC, Heintz APM. Epidemiology and etiology of squamous cell carcinoma of the vulva. Eur J Obstet Gynecol Reprod Biol. 1993;43:111-5.
3. Butt JL, Botha MH, Vulvar cancer is not a disease of the
elderly: Treatment and outcome at a tertiary referral centre in South Africa. S Afr Med J 2017;107:1000-4.
4. Gajjar K, Shafi M. Invasive vulval cancer, Obstetrics, Gynaecology and Reproductive Medicine 2014. Available from: http://dx.doi.org/10.1016/j.jogrnm.2014.04.006.
5. Anschau F, Afonso M, Gonçalves G. Gynecologic Cancers - Basic Sciences, Clinical and Therapeutic Perspectives. In: Farghaly SA, editor. Cancer of the Vulva - A review. Ch. 15. p. 315-30. doi: 10.5772/61579.
6. Kaban A, Kaban I, Afşar S. Surgical management of squamous cell vulvar cancer without clitoris, urethra or anus involvement. Gynecol Oncol Rep 2017;20:41-6.
7. Alkatout I, Schubert M, Garbrecht N, Weigel M, Jonat W, Mundhenke C, et al. Vulvar cancer: Epidemiology, clinical presentation, and management options. Int J Women's Health 2015;7:305-13.
8. World economic station and prospects 2014. UnitedNations publication. sales No. E.14.II.C.2. ISBN:978-92-1-109168-7. eISBN:978-92-1-054177-0.
9. Amavi AK, Kouadio L, Adabra K, Tengue K, Tijami F, Jalil A. Surgical management for squamous cell carcinoma of vulva. Pan Afr Med J 2016;24:145.
10. https://seer.cancer.gov/statfacts/html/vulva.html [Last Accessed on 2017 Apr 28].
11. Ciszko B, Pochwałowski M, St Gabryś M. Risk factors and clinical characteristic patients with vulvar cancer. Ginekol Pol 2006;77:914-21.
12. Singh N, Negi N, Srivastava K1, Agarwal G. A cohort study of vulvar cancer over a period of 10 years and review of literature. Indian J Cancer 2016;53:412-5.
13. Buttmann-Schweiger N, Klug SJ, Luynen A, Holleczek B, Heitz F, du Bois A, Kraywinkel K. Incidence patterns and temporal trends of invasive nonmelanotic vulva tumors in Germany 1999-2011. A population-based cancer registry analysis. PLoS One 2015;10:e0128073.
14. Okeke TC, Onah N, Ikeako LC, Ezenyeaku CCT. The frequency and pattern of female genital tract malignancies at the University of Nigeria teaching hospital, Enugu, Nigeria. Ann Med Health Sci Res 2013;3:345-8.
15. Baandrup L, Varbo A, Munk C, Johansen C, Frisch M, Kjaer SK. In situ and invasive squamous cell carcinoma of the vulva in Denmark 1978-2007-a nationwide population-based study. Gynecol Oncol 2011;122:45-9.
16. Okolo CA, Odubanjo MO, Awolude OA, Akang EE. A review of vulvar and vaginal cancers in Ibadan, Nigeria. N Am J Med Sci 2013;6:76-82.
17. Schuurman MS, van den Einden LC, Massuger LF, Kiemeney LA, van der Aa MA, de Hullu JA. Trends in incidence and survival of Dutch women with vulvar squamous cell carcinoma. Eur J Cancer 2013;49:3872.
18. Zongo N, Somé NK, Gang-Ny AM, Oumédraogo AS, et al. Cancer of the vulva in Burkina Faso: A hospital-based case series. Infect Agent Cancer 2016;11:33.
19. Stroup AM, Harlan LC, Trimble EL. Demographic, clinical, and treatment trends among women diagnosed with vulvar cancer in the United States. Gynecol Oncol 2008;108:577-83.
20. Dadzie MN, Aidoo CA, Vanderpuye V. Vulva cancer in Ghana – review of a hospital based data. Gynecol Oncol Rep 2017;20:108-11.
21. Dittmer C, Katalinic A, Mundhenke C, Thill M, Fischer D. Epidemiology of vulvar and vaginal cancer in Germany. Arch Gynecol Obstet 2011;284:1-7.
22. Hunter DJS. Carcinoma of the vulva: A review of 361 patients. Gynecol Oncol 1975;3:117-23.
23. Kehila M, Harabi S, Mhiri R, Touhami O, Abouda HS, Khlífi A, et al. Vulvar cancer in Tunisia: Epidemiological and clinicopathological features multicentric study. J Egypt Natl Canc Ins 2017;29:95-8.